Back to results
US 11,845,799 B2Granted
Anti-Ly6G6D antibodies and methods of use
AssigneeGenentech, Inc.
InventorsWeiYu Lin, Christoph Spiess, Liping Sun, Yan Wu, Cecilia P. C. Chiu, Walter Christian Darbonne, Michael Andrew Dillon
Life of this patent
Estimating the term…
Abstract
Provided herein are anti-Ly6G6D (lymphocyte antigen 6 complex, locus G61) antibodies and methods of using the same.
Claims44
A bispecific antibody that binds to lymphocyte antigen 6 family member G6D (LY6G6D) and cluster of differentiation 3 (CD3), wherein the bispecific antibody comprises:
- a LY6G6D binding domain comprising a heavy chain polypeptide (H1) and a light chain polypeptide (L1) and a CD3 binding domain comprising a heavy chain polypeptide (H2) and a light chain polypeptide (L2), wherein each H1 and H2 comprises a heavy chain variable domain (VH) and a heavy chain constant domain (CH1) and each L1 and L2 comprises a light chain variable domain (VL) and a light chain constant domain (CL), wherein:
- (a) the LY6G6D binding domain comprises the following six CDRs:
- (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 4;
- (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 5;
- (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 6;
- (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 1;
- (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 2;
- and
- (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 3;
- and
- (b) the CD3 binding domain comprises the following six CDRs:
- (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 15;
- (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 16;
- (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 17;
- (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 12;
- (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 13;
- and
- (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 14.
27 more elements
A bispecific antibody that binds to LY6G6D and CD3, wherein the bispecific antibody comprises:
- a LY6G6D binding domain comprising an H1 and an L1 and a CD3 binding domain comprising a heavy chain polypeptide (H2) and a light chain polypeptide (L2), wherein each H1 and H2 comprises a heavy chain variable domain (VH) and a heavy chain constant domain (CH1) and each L1 and L2 comprises a light chain variable domain (VL) and a light chain constant domain (CL), wherein:
- (a) the LY6G6D binding domain comprises the following six CDRs:
- (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 4;
- (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 5;
- (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 6;
- (iv) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 1;
- (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 2;
- and
- (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 3;
- and
- (b) the CD3 binding domain comprises the following six CDRs:
- (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 15;
- (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 16;
- (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 17;
- (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 12;
- (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 50;
- and
- (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 51.
27 more elements
A bispecific antibody that binds to LY6G6D and CD3, wherein the bispecific antibody comprises:
- a LY6G6D binding domain comprising a heavy chain polypeptide (H1) and a light chain polypeptide (L1) and a CD3 binding domain comprising a heavy chain polypeptide (H2) and a light chain polypeptide (L2), wherein each H1 and H2 comprises a heavy chain variable domain (VH) and a heavy chain constant domain (CH1) and each L1 and L2 comprises a light chain variable domain (VL) and a light chain constant domain (CL), wherein:
- the VH of H1 comprises the amino acid sequence of SEQ ID NO:
- 10;
- the VL of LA comprises the amino acid sequence of SEQ ID NO:
- 11;
- the VH of H2 comprises the amino acid sequence of SEQ ID NO:
- 20;
- and
- the VL of L2 comprises the amino acid sequence of SEQ ID NO:
- 21.
7 more elements
A bispecific antibody that binds to LY6G6D and CD3, wherein the bispecific antibody comprises:
- a LY6G6D binding domain comprising a heavy chain polypeptide (H1) and a light chain polypeptide (L1) and a CD3 binding domain comprising a heavy chain polypeptide (H2) and a light chain polypeptide (L2), wherein each H1 and H2 comprises a heavy chain variable domain (VH) and a heavy chain constant domain (CH1) and each L1 and L2 comprises a light chain variable domain (VL) and a light chain constant domain (CL), wherein:
- the VH of H1 comprises the amino acid sequence of SEQ ID NO:
- 59;
- the VL of L1 comprises the amino acid sequence of SEQ ID NO:
- 60;
- the VH of H2 comprises the amino acid sequence of SEQ ID NO:
- 89;
- and the VL of L2 comprises the amino acid sequence of SEQ ID NO:
- 90.
6 more elements
A bispecific antibody that binds to LY6G6D and CD3, wherein the bispecific antibody comprises:
- a LY6G6D binding domain comprising a heavy chain polypeptide (H1) and a light chain polypeptide (L1) and a CD3 binding domain comprising a heavy chain polypeptide (H2) and a light chain polypeptide (L2), wherein each H1 and H2 comprises a heavy chain variable domain (VH) and a heavy chain constant domain (CH1) and each L1 and L2 comprises a light chain variable domain (VL) and a light chain constant domain (CL), wherein:
- the VH of H1 comprises the amino acid sequence of SEQ ID NO:
- 10;
- the VL of L1 comprises the amino acid sequence of SEQ ID NO:
- 11;
- the VH of H2 comprises the amino acid sequence of SEQ ID NO:
- 20;
- and the VL of L2 comprises the amino acid sequence of SEQ ID NO:
- 55.
6 more elements
A bispecific antibody that binds to LY6G6D and CD3, wherein the bispecific antibody comprises:
- a LY6G6D binding domain comprising a heavy chain polypeptide (H1) and a light chain polypeptide (L1) and a CD3 binding domain comprising a heavy chain polypeptide (H2) and a light chain polypeptide (L2), wherein each H1 and H2 comprises a heavy chain variable domain (VH) and a heavy chain constant domain (CH1) and each L1 and L2 comprises a light chain variable domain (VL) and a light chain constant domain (CL), wherein:
- the VH of HI comprises the amino acid sequence of SEQ ID NO:
- 59;
- the VL of L1 comprises the amino acid sequence of SEQ ID NO:
- 60;
- the VH of H2 comprises the amino acid sequence of SEQ ID NO:
- 89;
- and the VL of L2 comprises the amino acid sequence of SEQ ID NO:
- 92.
6 more elements
Dependencies are inferred from the claim text.